Elranatamab
| Clinical data | |
|---|---|
| Trade names | Elrexfio |
| Other names | elranatamab-bcmm |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623045 |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6440H9958N1738O2010S49 |
| Molar mass | 145461.60 g·mol−1 |
Elranatamab, sold under the brand name Elrexfio, is a medication used for the treatment of multiple myeloma.[5][8][9][10] Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.[5][8] Elranatamab is administered subcutaneously.[5][8]
The most common side effects include cytokine release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia (fever).[8]
Elranatamab was approved for medical use in the United States in August 2023,[5][8][11] in the European Union in December 2023,[7] and in Canada in January 2024.[1]
Medical uses[edit]
Elranatamab is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[5][8]
Adverse effects[edit]
The most common adverse reactions include cytokine release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia.[8]
The US Food and Drug Administration (FDA) prescribing information for elranatamab has a boxed warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity.[8]
History[edit]
The safety and effectiveness of elranatamab was evaluated in MagnetisMM-3 (NCT04649359), an open-label, single-arm, multi-center study that included participants with relapsed/refractory multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody.[8] Overall, the study consisted of 97 participants naïve to prior BCMA-directed therapy and who had previously received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[8]
The FDA granted the application for elranatamab priority review, breakthrough therapy, and orphan drug designations;[8] and granted approval of Elrexfio to Pfizer Inc.[8]
Society and culture[edit]
Legal status[edit]
In October 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Elrexfio, intended for the treatment of multiple myeloma.[12] The applicant for this medicinal product is Pfizer Europe MA EEIG.[12]
Elranatamab was approved for medical use in the United States in August 2023,[5][8] in the European Union in December 2023,[7] and in Canada in January 2024.[1]
Brand names[edit]
Elranatamab is the international nonproprietary name.[13]
Elranatamab is sold under the brand name Elrexfio.[1][5][7]
References[edit]
- ^ a b c d "Elrexfio Product information". Health Canada. 22 October 2009. Retrieved 3 March 2024.
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-02-28]". Health Canada. 28 February 2024. Retrieved 2 March 2024.
- ^ "Details for: Elrexfio". Health Canada. 23 January 2024. Retrieved 3 March 2024.
- ^ "Regulatory Decision Summary for Elrexfio". Drug and Health Products Portal. 6 December 2023. Retrieved 2 April 2024.
- ^ a b c d e f g h "Elrexfio- elranatamab-bcmm injection, solution". DailyMed. 15 August 2023. Archived from the original on 18 August 2023. Retrieved 17 August 2023.
- ^ "Elrexfio- elranatamab-bcmm injection, solution". DailyMed. 16 August 2023. Archived from the original on 18 August 2023. Retrieved 17 August 2023.
- ^ a b c d "Elrexfio PI". Union Register of medicinal products. 8 December 2023. Retrieved 27 December 2023.
- ^ a b c d e f g h i j k l m "FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma". U.S. Food and Drug Administration (FDA) (Press release). 14 August 2023. Retrieved 14 August 2023.
This article incorporates text from this source, which is in the public domain.
- ^ Grosicki S, Bednarczyk M, Kociszewska K (2023). "Elranatamab: a new promising BispAb in multiple myeloma treatment". Expert Review of Anticancer Therapy. 23 (8): 775–782. doi:10.1080/14737140.2023.2236303. PMID 37434334. S2CID 259832018.
- ^ Dhillon S (November 2023). "Elranatamab: First Approval". Drugs. 83 (17): 1621–1627. doi:10.1007/s40265-023-01954-w. PMID 37924427. S2CID 265018550.
- ^ "Pfizer's Elrexfio Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma" (Press release). Pfizer. 14 August 2023. Retrieved 17 August 2023 – via Business Wire.
- ^ a b "Elrexfio EPAR". European Medicines Agency (EMA). 12 October 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information. 36 (1). hdl:10665/352794.
This article incorporates public domain material from the United States Department of Health and Human Services
External links[edit]
- "Elranatamab (Code C146860)". NCI Thesaurus.
- Clinical trial number NCT04649359 for "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |